Sixera pharma news

Month: June 2018

The start of something new

Welcome to our newly launched website were we will make it possible for you to follow our work and take part of insights from our

June 15, 2018 No Comments

Sixera Pharma Receives Rare Pediatric Disease Designation (RPDD) from FDA for SXR1096 for treatment of Netherton syndrome

July 5, 2022

Sixera initiates its first clinical trial on SXR1096 in Netherton Syndrome

December 7, 2021

Categories

Archives